Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11120792rdf:typepubmed:Citationlld:pubmed
pubmed-article:11120792lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:11120792lifeskim:mentionsumls-concept:C0025936lld:lifeskim
pubmed-article:11120792lifeskim:mentionsumls-concept:C0003320lld:lifeskim
pubmed-article:11120792lifeskim:mentionsumls-concept:C1762617lld:lifeskim
pubmed-article:11120792lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:11120792lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:11120792lifeskim:mentionsumls-concept:C1414550lld:lifeskim
pubmed-article:11120792lifeskim:mentionsumls-concept:C1414551lld:lifeskim
pubmed-article:11120792lifeskim:mentionsumls-concept:C1414552lld:lifeskim
pubmed-article:11120792lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:11120792lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:11120792lifeskim:mentionsumls-concept:C0599894lld:lifeskim
pubmed-article:11120792pubmed:issue12lld:pubmed
pubmed-article:11120792pubmed:dateCreated2000-12-21lld:pubmed
pubmed-article:11120792pubmed:abstractTextPrevious studies have documented that targeting foreign Ags to IgG FcgammaR leads to enhanced Ag-specific responses in vitro and in vivo. However, the ability to overcome immunologic nonresponsiveness by targeting poorly immunogenic Ags to FcgammaR has not been investigated. To address this question in a simple model, we immunized transgenic mice expressing human CD64 (FcgammaRI) and their nontransgenic littermates with Fab' derived from the murine anti-human CD64 mAb m22. The m22 Fab' served as both the targeting molecule and the Ag. We found that only CD64-expressing mice developed anti-Id titers to m22. Furthermore, chemically linked multimers of m22 Fab', which mediated efficient internalization of the human CD64, were significantly more potent than monomeric m22 F(ab')(2) at inducing anti-Id responses. In all cases, the humoral responses were specific for m22 Id and did not react with other murine IgG1 Fab' fragments. Chemical addition of a second murine Fab' (520C9 anti-human HER2/neu) to m22 Fab' multimers demonstrated that IgG1 and IgG2a anti-Id titers could be generated to 520C9 only in the CD64-expressing mice. These results show that targeting to CD64 can overcome immunological nonresponsiveness to a weak immunogen. Therefore, targeting to CD64 may be an effective method to enhance the activity of nonimmunogenic tumor vaccines.lld:pubmed
pubmed-article:11120792pubmed:languageenglld:pubmed
pubmed-article:11120792pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11120792pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11120792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11120792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11120792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11120792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11120792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11120792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11120792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11120792pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11120792pubmed:statusMEDLINElld:pubmed
pubmed-article:11120792pubmed:monthDeclld:pubmed
pubmed-article:11120792pubmed:issn0022-1767lld:pubmed
pubmed-article:11120792pubmed:authorpubmed-author:FeeW WWWlld:pubmed
pubmed-article:11120792pubmed:authorpubmed-author:GuyreP MPMlld:pubmed
pubmed-article:11120792pubmed:authorpubmed-author:GrazianoR FRFlld:pubmed
pubmed-article:11120792pubmed:authorpubmed-author:KelerTTlld:pubmed
pubmed-article:11120792pubmed:authorpubmed-author:VitaleL ALAlld:pubmed
pubmed-article:11120792pubmed:authorpubmed-author:Sundarapandiy...lld:pubmed
pubmed-article:11120792pubmed:authorpubmed-author:van De...lld:pubmed
pubmed-article:11120792pubmed:issnTypePrintlld:pubmed
pubmed-article:11120792pubmed:day15lld:pubmed
pubmed-article:11120792pubmed:volume165lld:pubmed
pubmed-article:11120792pubmed:ownerNLMlld:pubmed
pubmed-article:11120792pubmed:authorsCompleteYlld:pubmed
pubmed-article:11120792pubmed:pagination6738-42lld:pubmed
pubmed-article:11120792pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:meshHeadingpubmed-meshheading:11120792...lld:pubmed
pubmed-article:11120792pubmed:year2000lld:pubmed
pubmed-article:11120792pubmed:articleTitleTargeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice.lld:pubmed
pubmed-article:11120792pubmed:affiliationMedarex, Inc., Annandale, NJ 08801, USA. tkeler@injersey.comlld:pubmed
pubmed-article:11120792pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11120792lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11120792lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11120792lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11120792lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11120792lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11120792lld:pubmed